Buscar
Medicus Pharma Ltd
MDCXAñadir a la lista de seguimiento
0.275USD
+0.013+4.80%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
11.01MCap. mercado
PérdidaP/E TTM
Más Datos de Medicus Pharma Ltd Compañía
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
Información de Medicus Pharma Ltd
Símbolo de cotizaciónMDCX
Nombre de la empresaMedicus Pharma Ltd
Fecha de salida a bolsaOct 11, 2023
Director ejecutivoBokhari (Raza)
Número de empleados12
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 11
Dirección300 Conshohocken State Rd.
CiudadCONSHOHOCKEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19428
Teléfono16105407515
Sitio Webhttps://medicuspharma.com/
Símbolo de cotizaciónMDCX
Fecha de salida a bolsaOct 11, 2023
Director ejecutivoBokhari (Raza)
Ejecutivos de Medicus Pharma Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F. Bonner
Ms. Carolyn F. Bonner
President, Chief Financial Officer
President, Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Edward J. Brennan, Jr., M.D.
Dr. Edward J. Brennan, Jr., M.D.
Chief Scientific Officer, Head of Research and Development Program
Chief Scientific Officer, Head of Research and Development Program
--
--
Dr. Larry R. Kaiser
Dr. Larry R. Kaiser
Independent Director
Independent Director
--
--
Mr. Robert J. Ciaruffoli, CPA
Mr. Robert J. Ciaruffoli, CPA
Lead Independent Director
Lead Independent Director
--
--
Mr. Frank W. Lavelle
Mr. Frank W. Lavelle
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F. Bonner
Ms. Carolyn F. Bonner
President, Chief Financial Officer
President, Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Medicus Pharma Ltd?
Los cinco principales accionistas de Medicus Pharma Ltd son: Dr. Raza Bokhari, M.D.
¿Cuántas instituciones poseen acciones de Medicus Pharma Ltd (MDCX)?
A fecha de 2026Q1, 38 instituciones poseen acciones de Medicus Pharma Ltd, con un valor de mercado combinado de aproximadamente 4.15M, lo que representa el 7.52% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1672664.00.